ARTICLE SUMMARY:
The continuous glucose monitoring market is dominated by Abbott, Dexcom, and Medtronic, but this $10+ billion worldwide opportunity has attracted several others, including two innovative start-ups—Biolinq and Allez Health—that closed on substantial investment rounds this year and one longstanding competitor, Senseonics, that recently launched the first year-long CGM implantable.
The continuous glucose monitoring (CGM) market is dominated by three large players: Abbott, Dexcom, and Medtronic, with Abbott and Dexcom taking the lion’s share. Their efforts over the past decade to deliver more patient-friendly CGM solutions, prove the clinical value of the technology, and make it more accessible to a wide range of people have transformed CGM from a niche device category into the widely recognized standard of care for many people with diabetes, creating a $10+ billion annual worldwide market in the process.
That success, and the market’s ongoing growth potential, have spawned a growing list of follow-on competitors, including several innovative start-ups, hoping to carve out their own niche in this space. Whether or not they can do so will depend a lot on how this market evolves and matures over the next several years. But the sheer size of the opportunity is fostering a good deal of innovation and investor interest.
